ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2018
Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology.International journal of clinical oncology · 2024Guideline
- Clinical characteristics and prognosis of elderly patients with gastric gastrointestinal stromal tumors: a population-based study.Translational cancer research · 2025Article
- Domestic research on extra-gastrointestinal stromal tumors: A ten-year review.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
- A radiomics-clinical combined nomogram-based on non-enhanced CT for discriminating the risk stratification in GISTs.Journal of cancer research and clinical oncology · 2023Article
- Gastro-intestinal stromal tumor (GIST): Experience from a tertiary care center in a low resource country.Turkish journal of surgery · 2022Article
- Associations of CD34, Ki67, layer of invasion and clinical pathological characteristics, prognosis outcomes in gastrointestinal stromal tumors-a retrospective cohort study.Translational cancer research · 2022Article
- Prognostic Nomogram for Gastrointestinal Stromal Tumors after Surgery Based on the SEER Database.BioMed research international · 2022Article
- The Relationship of Clinicopathological Findings and PDGFR-β Expression With Tumor Recurrence in Gastrointestinal Stromal Tumors.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- A Retrospective Study of Postoperative Outcomes in 98 Patients Diagnosed with Gastrointestinal Stromal Tumor (GIST) of the Upper, Middle, and Lower Gastrointestinal Tract Between 2009 and 2019 at a Single Center in Poland.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Unusual presentations, management and outcomes of gastric stromal tumors: a single-center case series.Annals of gastroenterology · 2021Article
- Clinical and Prognostic Significance of Tumor-Infiltrating CD8+ T Cells and PD-L1 Expression in Primary Gastrointestinal Stromal Tumors.Frontiers in oncology · 2021Article
- Gastrointestinal stromal tumor of the excluded stomach after Roux-en-Y gastric bypass: A case report and literature review.International journal of surgery case reports · 2020Article
- A rare case of Wild-Type GIST of descending colon with GANT characteristics.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Article
- Chondroid gastrointestinal stromal tumor in the stomach with early adenocarcinoma.International journal of clinical and experimental pathology · 2019Article
- Establishment and Verification of Prognostic Nomograms for Patients with Gastrointestinal Stromal Tumors: A SEER-Based Study.BioMed research international · 2019Article
- Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe.Visceral medicine · 2018Review
- Controversies in EUS: Do we need miniprobes?Endoscopic ultrasoundArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to evaluate the clinicopathologic characteristics, immunohistochemical expression and prognostic factors of patients with primary gastrointestinal stromal tumors (GISTs). Methods: Data from 2,570 consecutive GIST patients from four medical centers in China (January 2001-December 2015) were reviewed. Survival curves were constructed by the Kaplan-Meier method, and Cox regression models were used to identify independent prognostic factors. Results: Of the included patients, 1,375 (53.5%) were male, and the patient age range was 18 to 95 (median, 58) years. The tumors were mostly found in the stomach (64.5%), small intestine (25.1%) and colorectal region (5.1%). At the time of diagnosis, the median tumor size was 4.0 (range: 0.1-55.0) cm, and the median mitotic index per 50 high power fields (HPFs) was 3 (range: 0-254). Of the 2,168 resected patients, 2,009 (92.7%) received curative resection. According to the modified National Institutes of Health (NIH) classification, 21.9%, 28.9%, 14.1% and 35.1% were very low-, low-, intermediate- and high-risk tumors, respectively. The rate of positivity was 96.4% for c-Kit, 87.1% for CD34, 96.9% for delay of germination 1 (DOG-1), 8.0% for S-100, 31.0% for smooth muscle actin (SMA) and 5.1% for desmin. However, the prognostic value of each was limited. Multivariate analysis showed that age, tumor size, mitotic index, tumor site, occurrence of curative resection and postoperative imatinib were independent prognostic factors. Furthermore, we found that high-risk patients benefited significantly from postoperative imatinib (P<0.001), whereas intermediate-risk patients did not (P=0.954). Conclusions: Age, tumor size, mitotic index, tumor site, occurrence of curative resection and postoperative imatinib were independent prognostic factors in patients with GISTs. Moreover, determining whether intermediate-risk patients can benefit from adjuvant imatinib would be of considerable interest in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.